Sol Barer - Edge Therapeutics Chairman of the Board
Chairman
Dr. Sol J. Barer, Ph.D. is Independent Chairman of the Board of Edge Therapeutics, Inc. Dr. Barer has served on our board of directors since September 2011 and was Chairman of our board of directors since January 2013. He is the Managing Partner of SJ Barer Consulting. Dr. Barer spent 24 years at Celgene as, among other positions, President, COO and CEO, as well as its Executive Chairman and Chairman before retiring in June 2011. Dr. Barer currently serves as Chairman of the Board of Teva Pharmaceutical Industries Ltd., Lead Independent Director of the Board of ContraFect Corporation, a biotechnology company and Chairman of the Board of Aevi Genomic Medicine, Inc., a genomic medicine company since 2013.
| Age | 70 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 800 208-3343 |
| Web | www.edgetherapeutics.com |
Edge Therapeutics Management Efficiency
Edge Therapeutics' management efficiency ratios could be used to measure how well Edge Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 4.17 M in liabilities with Debt to Equity (D/E) ratio of 47.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Edge Therapeutics has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Edge Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Edge Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edge Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edge to invest in growth at high rates of return. When we think about Edge Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Patrice Motsepe | Harmony Gold Mining | 56 | |
| Clark Kokich | Marchex | 63 | |
| Seifollah Ghasemi | Air Products and | 80 | |
| F Stepan | Stepan Company | 79 | |
| Belgacem Chariag | Ecovyst | 58 | |
| Douglas Ford | Air Products and | 69 | |
| Modise Motloba | Harmony Gold Mining | 51 | |
| Kevin Zugibe | Hudson Technologies | 51 | |
| Nicolas Hanauer | Marchex | 54 | |
| Frank Stepan | Stepan Company | 60 | |
Management Performance
| Return On Equity | -0.0086 | |||
| Return On Asset | -1.0E-4 |
Edge Therapeutics Leadership Team
Elected by the shareholders, the Edge Therapeutics' board of directors comprises two types of representatives: Edge Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edge. The board's role is to monitor Edge Therapeutics' management team and ensure that shareholders' interests are well served. Edge Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edge Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Macdonald, Chief Scientific Officer, Director | ||
| Tuija Soanjarvi, Director | ||
| Johan Bolin, Vice President Products | ||
| Antonio Perna, Co-founder, Business Coordinator Central Italy; Executive Director | ||
| KaiOlaf Dammenhain, Partner, Operations Germany | ||
| Joerg Kayser, Partner, Operations Germany | ||
| Tom Schmitt, Vice President Sales | ||
| Albert Marchio, Chief Accounting and Operations Officer | ||
| Gabriel Puente, Operations, Mexico/Managing Director of Techedge Mexico | ||
| Anders Hove, Independent Director | ||
| Vincenzo Perrone, Independent Director | ||
| Andrew CPA, CFO | ||
| Enrico Negroni, Chairman of the Board | ||
| Sabina Catalano, IR Contact Officer | ||
| Domenico Restuccia, Founder, CEO, Director | ||
| Giuseppe Vargas, Independent Director | ||
| Kelly McGurk, Director of Marketing and Communications | ||
| Bradford Middlekauff, Senior Vice President General Counsel, Secretary | ||
| Goran Appelquist, CTO | ||
| Andrew Saik, CFO | ||
| Gunilla Ohman, Investor Relations Manager | ||
| Florideo Fabrizio, Co-founder, Research & Development | ||
| Brian Leuthner, Co-Founder, CEO and President and Director | ||
| Erika Giannetti, Partner, Finance/CFO; Executive Director | ||
| Gregory Gin, IR Contact Officer | ||
| Jonas Hasselberg, Director | ||
| Rosemary Crane, Director | ||
| James Loughlin, Independent Director | ||
| Massimo Compagnoni, Partner, People | ||
| Richard Berg, General Counsel | ||
| Jose Rodriguez, Co-founder, Managing Partner Iberia & LATAM, Executive Director | ||
| Arnd Benninghoff, Director | ||
| Roberto Candido, Partner, Industrial & Services Sector Director | ||
| Isaac Blech, Independent Vice Chairman of the Board | ||
| Herbert DO, Chief Medical Officer | ||
| Fermin Carbajales, Partner, Operations Colombia | ||
| Daniel Brennan, COO | ||
| Pietro Migliavacca, Co-founder, Operations Italy | ||
| Eva Garcia, Partner, Sales Spain | ||
| Loch Macdonald, Chief Scientific Officer, Director | ||
| Andrew Einhorn, CFO | ||
| Herbert Faleck, Chief Medical Officer | ||
| Sergio Cipolla, Partner, Operations North America/Managing Director of North America | ||
| Jose Soares, Operations, Portugal/Managing Director of Techedge Portugal | ||
| Kurt Conti, Independent Director | ||
| James Healy, Independent Director | ||
| Annachiara Svelto, Independent Director | ||
| Liam Ratcliffe, Independent Director | ||
| Albert II, Chief Accounting and Operations Officer | ||
| Karl Thedeen, CEO, Managing Director | ||
| Sigrun Hjelmquist, Independent Director | ||
| Beatriz Reyero, Independent Director | ||
| Sol Barer, Chairman of the Board | ||
| Kent Sander, Independent Director | ||
| Giorgio Racca, Partner, Business Development; Executive Director | ||
| Michael Ruffolo, Independent Chairman of the Board | ||
| Andrea Lavazzi, Partner, Energy & Utilities Sector | ||
| Alyssa Wyant, Senior Vice President Regulatory Affairs | ||
| BengtArne Molin, Vice President - Research & Development | ||
| Jose Navarro, Partner, Operations LATAM; Executive Director | ||
| Robert Spiegel, Independent Director | ||
| Richard Brandon, Chief Marketing Officer | ||
| Magnus Larsson, Vice President - Operations |
Edge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edge Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0086 | |||
| Return On Asset | -1.0E-4 | |||
| Current Valuation | (18.81 M) | |||
| Shares Outstanding | 31.51 M | |||
| Shares Owned By Insiders | 5.63 % | |||
| Shares Owned By Institutions | 28.21 % | |||
| Number Of Shares Shorted | 727.39 K | |||
| Price To Earning | (7.05) X | |||
| Price To Book | 0.53 X | |||
| EBITDA | (30.18 M) |
Pair Trading with Edge Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edge Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edge Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Omnicom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Omnicom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Omnicom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Omnicom Group to buy it.
The correlation of Omnicom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Omnicom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Omnicom Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Omnicom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Edge Therapeutics information on this page should be used as a complementary analysis to other Edge Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Edge Stock
If you are still planning to invest in Edge Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Edge Therapeutics' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |